Third Opinion Trial Synopsis
This study is looking at whether a new medicine called belantamab mafodotin is safe and effective to treat people with a type of cancer called Multiple Myeloma. They will test it by giving it to people with normal liver function and people whose liver doesn't work as well to see if it works the same for both.

Trial Summary
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and in matched RRMM participants with normal hepatic function.